Citations

Clear

3138 citation(s) found for "Smith, AM".

Sexual and Gender Minority Invisibility in Cancer Studies: A Call for Effective Recruitment Methods to Address Cancer Disparities
Rosser, B. R. Simon , Weideman, Ben C. D. , Rider, G. Nic , Jatoi, Aminah , Ecklund, Alexandra M. , Wheldon, Christopher W. , Talley, Kristine Mc , Kulasingam, Shalini , Smith, M. Kumi , Jacobs, David R. , West, William , Alley, Rhea , Talley, Kristine M C , Mitteldorf, Darryl , Ross, Michael W , Rider, G. Nic , Jacobs, David R

Mayo Clinic

Journal of Clinical Oncology | September 19, 2023 | Volume: 41 | Issue: 33 | Pages: 5093-5098

10.1200/jco.23.00655 | PMID 37725780 Get It

#LGBTQ+ people with cancer are invisibilized: A call for #intersectional cancer research (link here) #healthequity
BULK RNA-SEQ DECONVOLUTION OF IMAGE-LOCALIZED HIGGRADE GLIOMA BIOPSIES REVEALS MEANINGFUL CELLULAR STATES
Bond, Kamila M. , Vélez, Sebastián, Urcuyo, Javier , León, Gustavo De , Langworthy, Jazlynn , Sereduk, Christopher, Singleton, Kyle , Krishna, Chandan , Zimmerman, Richard S. , Patra, Devi P. , Smith, Kris A. , Donev, Kliment , Mrugała, Maciej M. , Hu, Leland , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Curtin, Lee , Velez, Sebastian, Hawkins‐Daarud, Andrea , Leon, Gustavo De, Sereduk, Chris , Jackson, Pamela , Bendok, Bernard R. , Nakaji, Peter , Baxter, Leslie C. , Al‐Dalahmah, Osama , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | September 16, 2023 | Volume: 25 | Issue: Supplement_3 | Pages: iii2-iii2

10.1093/neuonc/noad147.005 Get It

Abstract AIMS High-grade glioma continues to have dismal survival with current standard-of-care treatment, owing in part to its intra- and inter-patient heterogeneity. Typical diagnostic biopsies are taken from the dense tumor core to determine the presence of abnormal cells and the status of a few key genes (e.g. IDH1, MGMT). However, the tumor core is typically resected, leaving behind possibly genetically, transcriptomically and/or phenotypically distinct invasive margins that repopulate the disease. As these remaining populations are the ones ultimately being treated, it is important to know their compositional differences from the tumor core. We aim to identify the phenotypic niches defined by the relative composition of key cellular populations and understand their variation amongst patients. METHOD We have established an image-localized research biopsy study, that samples from both the invasive margin and tumor core. From this protocol, we currently have 202 samples from 58 patients with available bulk RNA-Seq, collected between Mayo Clinic and Barrow Neurological Institute. Using a single-cell reference dataset from our collaborators at Columbia University, we used CIBERSORTx, a deconvolution method, to predict relative abundances of 7 normal, 6 glioma, and 5 immune cell states for each sample. RESULTS We find that these cell state abundances connect to patient survival and show regional differences. For example, proneural glioma states were higher in invasive regions, whereas proliferative and mesenchymal states were higher in the tumor core. CONCLUSIONS Our analysis demonstrates a need to characterize the residual tissue following glioma resection to better understand the recurrent disease.
Consultation patterns before and after embedding pediatric palliative care into a pediatric hematology/oncology clinic
Greenmyer, Jacob R. , Ngo, Tiffany , Smith, Melissa M. , Collura, Christopher A. , Schiltz, Brenda , McCarthy, Sarah R. , McCarthy, Sarah , Smith, Melissa, Collura, Christopher, McCarthy, Sarah R , McCarthy, Sarah R.

Mayo Clinic

Pediatric Blood & Cancer | September 15, 2023 | Volume: 70 | Issue: 12 | Pages: No page available

10.1002/pbc.30663 | PMID 37710331 Get It

AbstractIntroductionPalliative care is a critical component of pediatric oncology care. Embedded pediatric palliative care (PPC) is relatively new in pediatric hematology/oncology (PHO) and may improve access, utilization, and quality of PPC. In June 2020, the Mayo Clinic PPC service transitioned from an afternoon, physically independent clinic to an all‐day clinic embedded within PHO.MethodsRetrospective chart review was used to quantify consultation rates from PHO to PPC in 12‐month study periods before and after establishment of an embedded clinic. Changes in descriptive statistics and consult patterns were calculated. Study periods were compared using either chi‐square or Fisher's exact tests for categorical variables and Wilcox rank sum tests for continuous variables.ResultsThere was an 89% increase in consultations from PHO to PPC after initiation of an embedded clinic (n = 20 vs. n = 38 per 12 months). The absolute number of completed outpatient consults increased from three (15% of visits) pre‐embedment to fourteen (37%) post‐embedment (p = .082). The median number of days from first oncology visit to PPC assessment was unchanged after embedment (36 vs. 47 days, p = .98). Consults for solid tumors increased from 22% (n = 4) pre‐embedment to 60% (n = 18) post‐embedment (p < .05). Consults for symptom management increased from 60% (n = 12) to 87% (n = 33) (p < .05).ConclusionsEmbedment of PPC into a PHO workspace was associated with an increased number of total consults, outpatient consults, solid tumor consults, and consults for symptom management. Our “partial‐PPO” model allowed for provision of PPC in the outpatient oncology setting in a clinic where there is not enough volume to support a full‐time oncology‐focused clinician team.
Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy
Lin, Heather , Diego, Emilia J. , Yang, Wei , Valero, Vicente , Mitchell, Melissa P. , White, Richard L. , Rauch, Gaiane M., Kuerer, Henry M. , Group, Exceptional Responders Study, Moseley, Tanya W. , Leung, Jessica WT, Huang, Monica L. , Arribas, Elsa , Parra, Raquel FD van la, Teshome, Mediget , Hwang, Rosa F. , Miggins, Makesha, Piotrowski, Matthew J., Refinetti, Ana P, Ehlers, Richard A., Colen, Jessica Suarez, Loveland‐Jones, Catherine, Lesnikowski, Beth Ann, Samiian, Laila, Chong, Clayton, Arribas, Elsa M , Johnson, Helen Margaret , Shen, Yu , Krishnamurthy, Savitri , Smith, Benjamin D. , Lucci, Anthony , Sun, Susie X. , Shaitelman, Simona Flora , Boughey, Judy C. , Rauch, Gaiane M. , Group, Exceptional Responders Study, Candelaria, Rosalind P. , Adrada, Beatriz E. , Hunt, Kelly K. , Bedrosian, Isabelle

Mayo Clinic

JAMA Network Open | September 14, 2023 | Volume: 6 | Issue: 9 | Pages: e2333933

10.1001/jamanetworkopen.2023.33933 | PMID 37707811 Get It

ImportancePatients should have an active role in decisions about pursuing or forgoing specific therapies in treatment de-escalation trials.ObjectiveTo evaluate longitudinal patient-reported outcomes (PROs) encompassing decisional comfort and health-related quality of life (HRQOL) among patients who elected to enroll in a clinical trial evaluating radiotherapy alone, without breast surgery, for invasive breast cancers with exceptional response to neoadjuvant systemic therapy (NST).Design, Setting, and ParticipantsProspective, single-group, phase 2 clinical trial at 7 US medical centers. Women aged 40 years or older with invasive cT1-2 N0-1 M0 triple-negative or human epidermal growth factor receptor 2 (ERBB2)–positive breast cancer with no pathologic evidence of residual disease following standard NST enrolled from March 6, 2017, to November 9, 2021. Validated PRO measures were administered at baseline and 6, 12, and 36 months post-radiotherapy. Data were analyzed from January to February 2023.InterventionsPRO measures included the Decision Regret Scale (DRS), Functional Assessment of Cancer Therapy—Lymphedema (FACT-B+4), and Breast Cancer Treatment Outcomes Scale (BCTOS).Main Outcomes and MeasuresChanges in PRO measure scores and subscores over time.ResultsAmong 31 patients, the median (IQR) age was 61 (56-66) years, 26 (84%) were White, and 26 (84%) were non-Hispanic. A total of 15 (48%) had triple-negative disease and 16 (52%) had ERBB2-positive disease. Decisional comfort was high at baseline (median [IQR] DRS score 10 [0-25] on a 0-100 scale, with higher scores indicating higher decisional regret) and significantly increased over time (median [IQR] DRS score at 36 months, 0 [0-20]; P &amp;lt; .001). HRQOL was relatively high at baseline (median [IQR] FACT-B composite score 121 [111-134] on a 0-148 scale, with higher scores indicating higher HRQOL) and significantly increased over time (median [IQR] FACT-B score at 36 months, 128 [116-137]; P = .04). Perceived differences between the affected breast and contralateral breast were minimal at baseline (median [IQR] BCTOS score 1.05 [1.00-1.23] on a 1-4 scale, with higher scores indicating greater differences) and increased significantly over time (median [IQR] BCTOS score at 36 months, 1.36 [1.18-1.64]; P &amp;lt; .001). At 36 months postradiotherapy, the cosmetic subscore was 0.45 points higher than baseline (95% CI, 0.16-0.74; P = .001), whereas function, pain, and edema subscores were not significantly different than baseline.Conclusions and RelevanceIn this nonrandomized phase 2 clinical trial, analysis of PROs demonstrated an overall positive experience for trial participants, with longitudinal improvements in decisional comfort and overall HRQOL over time and minimal lasting adverse effects of therapy.Trial RegistrationClinicalTrials.gov Identifier: NCT02945579
Outcomes of asymptomatic histologic pyelonephritis of kidney transplant
Budhiraja, Pooja , Butterfield, Richard , Gea‐Banacloche, Juan , Swaminathan, Sundararaman , Khamash, Hassan A., Me, Hay Me , Kodali, Lavanya , Nair, S. , Misra, Suman , Heilman, Raymond L. , Mour, Girish K., Nair, Sumi, Heilman, Raymond , Budhiraja, Pooja , Smith, Maxwell L. , Mour, Girish

Mayo Clinic

Clinical Transplantation | September 14, 2023 | Volume: 37 | Issue: 12 | Pages: No page available

10.1111/ctr.15125 | PMID 37705388 Get It

AbstractBackgroundUrinary Tract Infections are the most common post‐transplant infection and can have varied presentations. This study aimed to describe the outcomes of kidney transplant recipients with asymptomatic histologic pyelonephritis on allograft biopsy. Histologic Pyelonephritis was defined as neutrophil cast or neutrophilic tubulitis, interstitial infiltrates with predominant neutrophils, and no evidence of rejection or glomerulonephritis on biopsy.MethodsThe study included 123 kidney transplant recipients, of whom 95 underwent protocol biopsies, and 28 had biopsies for elevated creatinine within the first 2 years of a kidney transplant.ResultsThe mean age of the cohort was 55.3 years, with 52% females and 78% deceased donor transplants. The risk factors for asymptomatic histologic pyelonephritis were recipient female sex (OR 1.89, 1.3–2.7, diabetes mellitus (OR 2.479, 1.687–3.645), and deceased donation (OR 1.69, 1.098–2.63). The incidence of asymptomatic pyelonephritis on protocol biopsy was 1.7%, with 52% having positive urine cultures and Escherichia coli being the most common bacteria. Subjects with asymptomatic pyelonephritis had inferior graft survival compared to the matched cohort HR 1.88 (1.06–3.35), p = .0281. In addition, of these 123 subjects, 68 (55%) subsequently developed pyelonephritis, and 34 subjects had pyelonephritis within 6 months after this episode. Subjects with recurrent infections exhibited lower survival HR 2.86 (1.36–6.02) and a trend toward higher rejection risk.ConclusionAsymptomatic histologic pyelonephritis can occur in kidney transplant recipients and is associated with inferior graft survival.
Florida-California Cancer Research, Education and Engagement (CaRE 2 ) Health Equity Center: Structure, Innovations, and Initial Outcomes
Reams, Renee, Carpten, John D. , Redda, Kinfe K. , Aparicio, Jose , Hensel, Brooke , Askins, Nissa, Abreu, Andre, Adams, Angela, Agyare, Edward , Ali, Jamel , Aló, Richard, Báezconde‐Garbanati, Lourdes , Brant, Jason O. , Brown, Clyde , Ezenwa, Miriam O. , Falzarano, Sara M. , Flores‐Rozas, Hernan , Fredenburg, Kristianna M. , Huang, Yong , Kiros, Gebre-Egziabher , Lamango, Nazarius S. , Lee, Ji‐Hyun , Lyon, Debra , Mitchell, Duane A. , Mochona, Bereket , Laird‐Offringa, Ite A. , Parker, Alexander S. , Richey, Joyce M., Rogers, Sherise C. , Salhia, Bodour , Schmittgen, Thomas D. , Segal, Richard , Smith, Ukamaka D. , Su, Li‐Ming , Suther, Sandra , Treviño, José G. , Velazquez‐Villarreal, Enrique , Webb, Fern J. , Wu, Anna H. , Yao, Yingwei , Wilkie, Diana J. , Hensel, Brooke , George, Thomas J , Velazquez-Villarreal, Enrique I , Wilkie, Diana J , Stern, Mariana Carla , Krieger, Janice L. , Allen, John M. , Buxbaum, Sarah G. , Cohen, Pinchas , Cozen, Wendy , Fillingim, Roger Benton , George, Thomas J. , Han, Bo , Halbert, Chanita Hughes , Nieva, Jorgé , Okunieff, Paul G , Rhie, Suhn K. , Setiawan, Veronica Wendy

Mayo Clinic

Cancer Control | September 13, 2023 | Volume: 30 | Issue: No issue available | Pages: No page available

10.1177/10732748231197878 | PMID 37703814 Get It

Introduction The Florida-California Cancer Research, Education, and Engagement (CaRE 2 ) Health Equity Center is a triad partnership committed to increasing institutional capacity for cancer disparity research, the diversity of the cancer workforce, and community empowerment. This article provides an overview of the structure, process innovations, and initial outcomes from the first 4 years of the CaRE 2 triad partnership. Methods CaRE 2 serves diverse populations in Florida and California using a “molecule to the community and back” model. We prioritize research on the complex intersection of biological, environmental, and social determinants health, working together with scientific and health disparities communities, sharing expertise across institutions, bidirectional training, and community outreach. Partnership progress and outcomes were assessed using mixed methods and four Program Steering Committee meetings. Results Research capacity was increased through development of a Living Repository of 81 cancer model systems from minority patients for novel cancer drug development. CaRE 2 funded 15 scientific projects resulting in 38 publications. Workforce diversity entailed supporting 94 cancer trainees (92 URM) and 34 ESIs (32 URM) who coauthored 313 CaRE 2 -related publications and received 48 grants. Community empowerment was promoted via outreaching to more than 3000 individuals, training 145 community cancer advocates (including 28 Community Scientist Advocates), and publishing 10 community reports. CaRE 2 members and trainees together have published 639 articles, received 61 grants, and 57 awards. Conclusion The CaRE 2 partnership has achieved its initial aims. Infrastructure for translational cancer research was expanded at one partner institution, and cancer disparities research was expanded at the two cancer centers.
CYP2D6 ‐guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial
Mosley, Scott A. , Cicali, Emily J. , Cueto, Alex Del, Portman, Diane , Donovan, Kristine A. , Gong, Yan , Langaee, Taimour , Gopalan, Priya, Schmit, Jessica M., Starr, Jason S. , Silver, Natalie L. , Chang, Young D. , Rajasekhara, Sahana , Smith, Joshua E., Clare‐Salzler, Michael , Starostik, Petr , McLeod, Howard L. , Hicks, J. Kevin , Cicali, Emily , George, Thomas J , Hicks, J Kevin , Cavallari, Larisa H , Soares, Heloisa P. , George, Thomas J. , Fillingim, Roger Benton , Cavallari, Larisa H.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | September 12, 2023 | Volume: 43 | Issue: 12 | Pages: 1286-1296

10.1002/phar.2875 | PMID 37698371 Get It

Abstract Introduction The CYP2D6 enzyme metabolizes opioids commonly prescribed for cancer‐related pain, and CYP2D6 polymorphisms may contribute to variability in opioid response. We evaluated the feasibility of implementing CYP2D6 ‐guided opioid prescribing for patients with cancer and reported pilot outcome data. Methods Adult patients from two cancer centers were prospectively enrolled into a hybrid implementation‐effectiveness clinical trial and randomized to CYP2D6 ‐genotype‐guided opioid selection, with clinical recommendations, or usual care. Implementation metrics, including provider response, medication changes consistent with recommendations, and patient‐reported pain and symptom scores at baseline and up to 8 weeks, were assessed. Results Most (87/114, 76%) patients approached for the study agreed to participate. Of 85 patients randomized, 71% were prescribed oxycodone at baseline. The median (range) time to receive CYP2D6 test results was 10 (3–37) days; 24% of patients had physicians acknowledge genotype results in a clinic note. Among patients with CYP2D6 ‐genotype‐guided recommendations to change therapy ( n = 11), 18% had a change congruent with recommendations. Among patients who completed baseline and follow‐up questionnaires ( n = 48), there was no difference in change in mean composite pain score (−1.01 ± 2.1 vs. −0.41 ± 2.5; p = 0.19) or symptom severity at last follow‐up (3.96 ± 2.18 vs. 3.47 ± 1.78; p = 0.63) between the usual care arm ( n = 26) and genotype‐guided arm ( n = 22), respectively. Conclusion Our study revealed high acceptance of pharmacogenetic testing as part of a clinical trial among patients with cancer pain. However, provider response to genotype‐guided recommendations was low, impacting assessment of pain‐related outcomes. Addressing barriers to utility of pharmacogenetics results and clinical recommendations will be critical for implementation success.
Estimating population impact of state triage policies restricting healthcare access for older adults with chronic conditions
Nguyen, Nicholas V. , Ennis, Jackson S. , Tilburt, Jon C. , Smith, Alexander K. , Kramer, Daniel B. , Sulmasy, Daniel P., DeMartino, Erin S. , Nguyen, N.V. , Riggan, Kirsten A.

Mayo Clinic

Journal of the American Geriatrics Society | September 11, 2023 | Volume: 72 | Issue: 1 | Pages: 294-296

10.1111/jgs.18589 | PMID 37694828 Get It

Electronic Patient-Reported Outcome Data Collection Systems in Oncology Clinical Trials: A Survey of Clinical Research Professionals (an Alliance Study)
Cho, Youmin , Zahrieh, David , Chow, Selina , Williams, David A. , Arnault, Denise Saint , Jiang, Yun , Lavoie Smith, Ellen M , Zahrieh, David , Williams, David A , Saint Arnault, Denise , Jiang, Yun

Mayo Clinic

JCO Clinical Cancer Informatics | September 7, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/cci.23.00007 | PMID 37677111 Get It

PURPOSE To describe clinical research professionals (CRPs)’ experiences with electronic patient-reported outcome (ePRO) data collection systems in oncology clinical trials and identify correlates of CRPs' attitude toward technology. METHODS An online survey was conducted among 210 CRPs from 125 National Cancer Institute–funded research sites. Measures included CRPs' demographic characteristics, working years, employment locations, and previous experiences with various types of ePROs. Their attitude toward technology was measured by the Technology Attitude Scale-Adapted. The Wilcoxon signed-rank test was used to compare two subdomains of attitude (perceived usefulness [PU] and perceived ease of use [PEU]). Multiple linear regression was used to explore correlates of (1) overall attitude, (2) PU, and (3) PEU. The significance level was 5%. RESULTS Participants' median age was 41 years (range, 21-67). Most were female (90%) and White (82%). More than half of the participants had previous experiences with web-based ePROs using patients' own devices (72%) or site-/sponsor-provided on-site devices (eg, kiosks or tablets; 64%). CRPs who were 60 years or older (β = −0.32, P < .05) or worked for 10-20 years (β = −0.11, P < .05) had relatively negative attitudes, controlling for other factors. Previous experiences with more ePRO types were associated with more positive attitudes (β = 0.08, P = .02). Similar correlates were found with PU but not with PEU. CONCLUSION This study revealed that CRPs had various experiences with ePRO systems and attitudes toward technology. Age, working years, and previous experiences with ePROs were correlates of overall attitude toward technology and PU. These findings suggest necessary targeted training to facilitate ePRO use in oncology clinical trials by improving CRPs' awareness and attitude toward technology.
NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023
Bevers, Therese B. , Niell, Bethany L. , Bonaccio, Ermelinda, Camp, Melissa , Chikarmane, Sona A. , Eghtedari, Mohammad , Flanagan, Meghan R. , Hawley, Jeffrey , Helvie, Mark A. , Hodgkiss, Linda, Hoyt, Tamarya L., Ivanovich, Jennifer , Kulkarni, Swati , Lancaster, Rachael, Mauer, Caitlin , Pearlman, Mark D. , Philpotts, Liane E. , Plichta, Jennifer K. , Shakeri, Shadi Aminololama, Smith, Mary Lou , Streibert, Clarie L., Strigel, Roberta M. , Tumyan, Lusine , Winkler, Nicole , Wolverton, Dulcy , Bergman, Mary Anne, Stehman, Katie, Plichta, Jennifer K , Baker, Jennifer L. , Bennett, Debbie Lee , Conant, Emily F. , Jochelson, Maxine S. , Maxwell, Jessica, Patel, Bhavika , Plecha, Donna , Kumar, Rashmi

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 6, 2023 | Volume: 21 | Issue: 9 | Pages: 900-909

10.6004/jnccn.2023.0046 | PMID 37673117 Get It

The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide health care providers with a practical, consistent framework for screening and evaluating a spectrum of clinical presentations and breast lesions. The NCCN Breast Cancer Screening and Diagnosis Panel is composed of a multidisciplinary team of experts in the field, including representation from medical oncology, gynecologic oncology, surgical oncology, internal medicine, family practice, preventive medicine, pathology, diagnostic and interventional radiology, as well as patient advocacy. The NCCN Breast Cancer Screening and Diagnosis Panel meets at least annually to review emerging data and comments from reviewers within their institutions to guide updates to existing recommendations. These NCCN Guidelines Insights summarize the panel’s decision-making and discussion surrounding the most recent updates to the guideline’s screening recommendations.